{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:48:58Z","timestamp":1794948538031,"version":"4.9.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarizes the current evidence on treatment strategies for inflammatory arthritis because of cancer treatment with immune checkpoint inhibitors (ICI), prognosis of ICI-induced arthritis, and management of patients with preexisting inflammatory arthritis receiving ICI therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Inflammatory arthritis is the most common rheumatic immune-related adverse event observed in patients receiving ICI therapy. Most patients can successfully be treated with low doses of corticosteroids or conventional synthetic disease modifying anti-rheumatic drugs (DMARDs). A small minority will develop severe symptoms requiring biologic therapy including TNF inhibitors and IL-6 receptor inhibitors. Many cases of inflammatory arthritis will resolve with cessation of ICI therapy. Some patients will develop persistent arthritis despite discontinuation. Patients with preexisting inflammatory arthritis (e.g. rheumatoid arthritis) commonly flare on ICI therapy, but can usually be managed with corticosteroids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Inflammatory arthritis following ICI therapy for cancer is relatively common and the practicing rheumatologist should be able to recognize and manage it in conjunction with Oncology. The majority of patients respond to corticosteroids, but some will need treatment with conventional synthetic or biologic DMARDs. Additional studies should investigate the effects of immunosuppression on tumor response and the use of ICI therapy in patients with preexisting autoimmune disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000701","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:46:08Z","timestamp":1583887568000},"page":"315-320","source":"Crossref","is-referenced-by-count":49,"title":["Treatment of immune checkpoint inhibitor-induced inflammatory arthritis"],"prefix":"10.1097","volume":"32","author":[{"given":"Susanna","family":"Jeurling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site \u2014 when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New emerging targets in cancer immunotherapy: the role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"(15 Suppl)","key":"R7-20230829","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of antilymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J Clin Oncol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11882-017-0740-z","article-title":"CHECKPOINT INHIBITORS: APPLICATIONS FOR AUTOIMMUNITY","volume":"17","author":"Tocheva","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R17-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10067-018-4035-0","article-title":"Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment","volume":"37","author":"Inamo","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR open Rheumatol"},{"issue":"(Suppl 4)","key":"R23-20230829","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in nonsmall cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of antiprogrammed death 1 antibodies in patients with cancer and preexisting autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on antitumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:12:35Z","timestamp":1693293155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000701","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}